<SEC-DOCUMENT>0001213900-24-078074.txt : 20240912
<SEC-HEADER>0001213900-24-078074.hdr.sgml : 20240912
<ACCEPTANCE-DATETIME>20240912141236
ACCESSION NUMBER:		0001213900-24-078074
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240912
DATE AS OF CHANGE:		20240912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MASIMO CORP
		CENTRAL INDEX KEY:			0000937556
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330368882
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33642
		FILM NUMBER:		241294598

	BUSINESS ADDRESS:	
		STREET 1:		52 DISCOVERY
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		949-297-7000

	MAIL ADDRESS:	
		STREET 1:		52 DISCOVERY
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ea0214392-defa14a_masimo.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE 14A INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of
the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Amendment No. )</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MASIMO CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Name of Registrant as Specified In Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if
other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Payment of Filing Fee (Check the appropriate box):</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">No fee required.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Fee paid previously with preliminary materials.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently valid OMB control number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>On September 12, 2024, Masimo Corporation (&ldquo;Masimo&rdquo;
or the &ldquo;Company&rdquo;) issued a press release regarding Masimo&rsquo;s 2024 Annual Meeting of Stockholders. A copy of the press
release is set forth below.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Masimo&rsquo;s Lawsuit Forced Politan and Quentin
Koffey to Issue Corrective Disclosures on False and Misleading Statements Made to Masimo Stockholders on Issues Material to the Proxy
Contest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>ISS and Glass Lewis Based Recommendations Upon
Politan&rsquo;s Lies; Egan-Jones Recommends &ldquo;FOR&rdquo; Both of Masimo&rsquo;s Director Nominees Following Multiple Corrective Disclosures
by Politan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Control of Masimo Depends on September 19 Vote
&ndash; Stockholders Urged to Vote &ldquo;FOR&rdquo; Only Masimo&rsquo;s Director Nominees, Joe Kiani and Christopher Chavez, on the Updated
GOLD Proxy Card</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 12, 2024 12:18 PM Eastern Daylight Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (&ldquo;Masimo&rdquo;
or the &ldquo;Company&rdquo;) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today set the
record straight in response to Politan Capital Management LP (&ldquo;Politan&rdquo;) and Quentin Koffey&rsquo;s preemptive press release
regarding an order from the U.S. District Court for the Central District of California that is still under seal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Masimo&rsquo;s lawsuit forced Politan to issue several new disclosures,
including on the morning of the hearing, to correct its false and misleading statements and to provide material information Politan previously
concealed from Masimo stockholders, ISS and Glass Lewis. These false and misleading statements include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Politan and Quentin Koffey Lied About the Spin-off.</B> Mr. Koffey falsely claimed that the Special Committee had unanimously rejected
the term sheet he had previously agreed upon with Mr. Kiani. In fact, Politan&rsquo;s corrective disclosures revealed that Mr. Koffey
never shared the agreed upon term sheet with any other member of the Special Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Politan and Quentin Koffey Lied About the Board&rsquo;s Role in the Sale Process.</B> Mr. Koffey falsely claimed that the Board
authorized Mr. Kiani to carry out a sale of the Company without further Board oversight. In fact, Politan&rsquo;s corrective disclosures
revealed that Mr. Koffey knew this not to be true.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Politan and Quentin Koffey Lied About the Outcome of the Sale Process.</B> Mr. Koffey falsely implied that Mr. Kiani unilaterally
rejected offers for Masimo because those offers didn&rsquo;t satisfy Mr. Kiani personally. In fact, Politan&rsquo;s corrective disclosures
revealed that Mr. Koffey knew that Masimo had not received or rejected any offers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Masimo issued the following statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;Politan and Quentin Koffey have relied on misleading
and false statements to distract both stockholders and proxy advisory firms from their lack of a plan or strategy for Masimo. In stark
contrast, Masimo has made concrete commitments to usher in changes that stockholders have said they want, including separating our consumer
business and expanding the Board with more independent directors. Our recent earnings clearly show that our strategy is working. We urge
stockholders not to put this momentum at risk by handing control to an inexperienced team with no strategy or leadership plan for the
business, particularly in light of the fact that Mr. Kiani has been clear about his intentions to depart the Company should Politan gain
control of the Board. Masimo&rsquo;s COO, Bilal Muhsin, has also declared his intent to resign if Politan gains control of the Board,
and more than three hundred other employees, including senior executives, have expressed that they may follow suit.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The September 19, 2024 Annual Meeting is fast approaching, and it&rsquo;s
important to vote as soon as possible</B>. The Company urges stockholders to vote &ldquo;FOR&rdquo; Masimo&rsquo;s director nominees,
Joe Kiani and Christopher Chavez, on the updated <B>GOLD</B> proxy card to protect Masimo&rsquo;s future and your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information on how to protect the value of your investment
at Masimo, visit www.ProtectMasimosFuture.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 6pt; padding-left: 6pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-left: black 1pt solid; border-right: black 1pt solid; padding-right: 6pt; padding-left: 6pt; font-size: 10pt; text-align: center"><B>Your Vote Is Important, Please Use The Updated&nbsp;<U>GOLD</U>&nbsp;Proxy Card Today!</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-left: black 1pt solid; border-right: black 1pt solid; padding-right: 6pt; padding-left: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-left: black 1pt solid; border-right: black 1pt solid; padding-right: 6pt; padding-left: 6pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-left: black 1pt solid; border-right: black 1pt solid; padding-right: 6pt; padding-left: 6pt; font-size: 10pt; text-align: center">If you have questions about how to vote your shares, please call the firm assisting us with the solicitation of proxies,</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-left: black 1pt solid; border-right: black 1pt solid; padding-right: 6pt; padding-left: 6pt; font-size: 10pt; text-align: center"><B>Innisfree M&amp;A Incorporated</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-left: black 1pt solid; border-right: black 1pt solid; padding-right: 6pt; padding-left: 6pt; font-size: 10pt; text-align: center"><B>1 (877) 456-3463 (toll-free from the U.S. and Canada)</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-left: black 1pt solid; border-right: black 1pt solid; padding-right: 6pt; padding-left: 6pt; font-size: 10pt; text-align: center"><B>or</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-left: black 1pt solid; border-right: black 1pt solid; padding-right: 6pt; padding-left: 6pt; font-size: 10pt; text-align: center"><B>+1 (412) 232-3651 (from other locations)</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-left: black 1pt solid; border-bottom: Black 1pt solid; border-right: black 1pt solid; padding-right: 6pt; padding-left: 6pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Masimo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Masimo (NASDAQ: MASI) is a global medical technology company that develops
and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and
automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers &amp;
Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo
SET &reg; Measure-through Motion and Low Perfusion &trade; pulse oximetry, introduced in 1995, has been shown in over 100 independent
and objective studies to outperform other pulse oximetry technologies. 1 Masimo SET &reg; has also been shown to help clinicians reduce
severe retinopathy of prematurity in neonates, 2 improve CCHD screening in newborns 3 and, when used for continuous monitoring with Masimo
Patient SafetyNet &trade; in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. 4-5 Masimo SET &reg;
is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world, 6 and is
the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2024 Newsweek World&rsquo;s Best Hospitals listing. 7 In 2005,
Masimo introduced rainbow &reg; Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin (SpHb &reg; ), oxygen content (SpOC &trade; ), carboxyhemoglobin
(SpCO &reg; ), methemoglobin (SpMet &reg; ), Pleth Variability Index (PVi &reg; ), RPVi &trade; (rainbow &reg; PVi), and Oxygen Reserve
Index (ORi &trade; ). In 2013, Masimo introduced the Root &reg; Patient Monitoring and Connectivity Platform, built from the ground up
to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo
additions include Next Generation SedLine &reg; Brain Function Monitoring, O3 &reg; Regional Oximetry, and ISA &trade; Capnography with
NomoLine &reg; sampling lines. Masimo&rsquo;s family of continuous and spot-check monitoring Pulse CO-Oximeters &reg; includes devices
designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7 &reg;
, Radius PPG &reg; , and Radius VSM &trade; , portable devices like Rad-67 &reg; , fingertip pulse oximeters like MightySat &reg; Rx,
and devices available for use both in the hospital and at home, such as Rad-97 &reg; and the Masimo W1 &reg; medical watch. Masimo hospital
and home automation and connectivity solutions are centered around the Masimo Hospital Automation &trade; platform, and include Iris &reg;
Gateway, iSirona &trade; , Patient SafetyNet, Replica &reg; , Halo ION &reg; , UniView &reg; , UniView :60 &trade; , and Masimo SafetyNet
&reg; . Its growing portfolio of health and wellness solutions includes Radius T&ordm; &reg; , Masimo W1 Sport, and Masimo Stork &trade;
.. Additional information about Masimo and its products may be found at www.masimo.com . Published clinical studies on Masimo products
can be found at https://professional.masimo.com/evidence/featured-studies/feature/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>References</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Published clinical studies on pulse oximetry and the benefits of Masimo SET &reg; can be found on our website at www.masimo.com. Comparative
studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed
journal articles.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology.
Acta Paediatr. 2011 Feb;100(2):188-92.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD>de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD>McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD>McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2021; 17(8):557-561.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD>Estimate: Masimo data on file.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">7.</TD><TD>As ranked in the 2024 Newsweek World&rsquo;s Best Hospitals listing, available at https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, in connection
with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding
the 2024 Annual Meeting of Stockholders (the &ldquo;2024 Annual Meeting&rdquo;) of Masimo and the potential stockholder approval of the
Board&rsquo;s nominees; changes to Masimo's governance, including the composition of Masimo's Board of Directors and Masimo's plans to
expand the Board; and the proposed separation of Masimo&rsquo;s consumer business, including any potential joint venture or any other
potential separation of Masimo&rsquo;s consumer business. These forward-looking statements are based on current expectations about future
events affecting Masimo and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond
Masimo&rsquo;s control and could cause its actual results to differ materially and adversely from those expressed in its forward-looking
statements as a result of various risk factors, including, but not limited to (i) uncertainties regarding future actions that may be taken
by Politan in furtherance of its nomination of director candidates for election at the 2024 Annual Meeting, (ii) the potential cost and
management distraction attendant to Politan&rsquo;s nomination of director nominees at the 2024 Annual Meeting and (iii) factors discussed
in the &ldquo;Risk Factors&rdquo; section of Masimo&rsquo;s most recent periodic reports filed with the Securities and Exchange Commission
(&ldquo;SEC&rdquo;), which may be obtained for free at the SEC&rsquo;s website at www.sec.gov. Although Masimo believes that the expectations
reflected in its forward-looking statements are reasonable, the Company does not know whether its expectations will prove correct. All
forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today&rsquo;s date. Masimo does
not undertake any obligation to update, amend or clarify these statements or the &ldquo;Risk Factors&rdquo; contained in the Company&rsquo;s
most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required
under the applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information Regarding the 2024 Annual Meeting of Stockholders
and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 15, 2024, the Company filed a revised version of its 2024
proxy statement (the &ldquo;Revised Proxy Statement&rdquo;) and has mailed the Revised Proxy Statement to its stockholders of record as
of the new August 12, 2024 record date for the 2024 Annual Meeting. Any votes submitted by Masimo stockholders in connection with the
2024 Annual Meeting prior to the filing of the Revised Proxy Statement will not be counted and previous proxies submitted will be disregarded,
and therefore, all stockholders will need to resubmit their votes, even if they have previously voted. The Company filed a revised version
of the Revised Proxy Statement with the SEC on August 22, 2024, which amended, superseded and replaced in its entirety the Revised Proxy
Statement (the &ldquo;Amended Revised Proxy Statement&rdquo;). THE COMPANY&rsquo;S STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE AMENDED
REVISED PROXY STATEMENT (AND ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ACCOMPANYING UPDATED GOLD PROXY CARD AS THEY CONTAIN IMPORTANT
INFORMATION. Stockholders may obtain the Amended Revised Proxy Statement and any amendments or supplements thereto and other documents
as and when filed by the Company with the SEC without charge from the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Information Regarding Participants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company, its directors and certain of its executive officers and
employees may be deemed to be participants in connection with the solicitation of proxies from the Company&rsquo;s stockholders in connection
with the matters to be considered at the 2024 Annual Meeting. Information regarding the direct and indirect interests, by security holdings
or otherwise, of the Company&rsquo;s directors and executive officers in the Company is included in the Amended Revised Proxy Statement,
which can be found through the SEC&rsquo;s website at https://www.sec.gov/ix?doc=/Archives/edgar/data/937556/000121390024071554/ea0206756-07.htm,
and any changes thereto may be found in any amendments or supplements to the Amended Revised Proxy Statement and other documents as and
when filed by the Company with the SEC, which can be found through the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact: Eli Kammerman</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(949) 297-7077</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ekammerman@masimo.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact: </B>Evan Lamb</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(949) 396-3376</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">elamb@masimo.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] '0# 2(  A$! Q$!_\0
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M>'Y;]E5[ACY=M$3]^0]/P'4_2OGZYUK6-5O3>7NHW+SDYRLA0+] .!^%=/\
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M[$.OY]/QKZ$\5*%\%ZV , :?/@?]LS6?X(\&:?X1TPQ6Q,US-@SW+C#/Z#V
M]*TO%H_XH[7/^P?/_P"BS6E./*C@S+&/%5;K9;'-ZC8_VC\"GML EM 5QGU$
M(8?J*H^'[/[#^SMY."-VASR\_P#32-W_ /9JZSPW"MS\/](@8D+)I<*DCWB
MJKK=G'I_PIU&SBXCM]%DB3 QPL) _E6AYAXS\.U$_P '9;%PICO?$UK;-N&>
M#) 3QWZ5T_QWT33],\':?J.G:=:VTUOJ,9+0PJG!5NN!ZA:Y?X7-_P 45H2$
M9#>,H_TM\_TKTCXZ0"7X5W[$D&*:%QCN=X']: /0[>5;BVBF4@B1 P(Z'(KY
MH@AC_P"%<?%.]@(^RS:I$D6!Q@7&>/P<5;^(?B3Q)I.B^%[G3M<N;6UU71[<
M/:Q<*AV<D'WSVQTKI]>\,VOA;]G&^L;=S*TR0W,LK+@N[31GI[# _"@#6/\
MR#?A-_OQ?^DIK#\':;]F\?\ Q1E ^6-)%R_7]YO?\N/Y5N'_ )!OPF_WXO\
MTE-:EGIT=OKWQ&N0VY[A8MV1T MNGZT >>Z1I#:S^R[<0QJ3+!)+<H!_TSER
M?TS787OB>+_AG?\ M4.BF721:C'_ #U(\HC\\U/\#8TD^$UDDBAD::<%3T(W
MFN$D\ ;OB2O@#^V;K_A&@3J@L]O3)_U><^G&?TSS0!Z=\)-)?2OAAHD,@99)
?8C<,/^NC%A^A%%=FEND<:1QJ$C10JJ!P .U% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
